CHCWM – Cancer & Hematology Centers of West Michigan

M21-404 (Abbvie)

Description:  Advanced Solid Tumors:   ABBV-400 as Monotherapy-A Global First-in-Human Study


Mechanism of Action: Antibody drug conjugate targeting c-MET with a topoisomerase inhibitor payload


Target Patient Population: All solid tumors


Study Design: Study drug is administered IV every 3 weeks


For more information on this trial, read its profile on here.